Boston Scientific has signed a definitive agreement to acquire Vessix Vascular, developer of a catheter-based renal denervation system for the treatment of uncontrolled hypertension. Boston Scientific announced that the acquisition is expected to close by the end of November 2012.
“Hypertension is a major global healthcare challenge, affecting more than one billion people worldwide,” said Mike Mahoney, president and chief executive officer at Boston Scientific. “Renal denervation represents a potential breakthrough therapy for the treatment of uncontrolled hypertension and is an important part of the Boston Scientific growth strategy. The acquisition of Vessix Vascular adds a second generation, highly differentiated technology to our hypertension strategy while accelerating our entry into what we expect to be a multi-billion dollar market by 2020.”
The Vessix Vascular V2 Renal Denervation System has received CE mark in Europe and TGA approval in Australia. Vessix Vascular has initiated the REDUCE-HTN post-market surveillance study and expects to initiate a full launch of the product in CE mark countries in 2013.
“The Vessix system offers the potential for a significant step forward in the treatment of uncontrolled hypertension,” said Horst Sievert, director of the CardioVascular Center Frankfurt, Sankt Katharinen Hospital, in Frankfurt, Germany. “In my experience, the system offers ease of use, faster treatment times with decreased patient discomfort and an intuitive approach to renal denervation that leverages the expertise of the interventionalist with balloon catheter technology.”
“We expect that hypertension therapies will be a key growth driver for Boston Scientific going forward,” said Jeff Mirviss, president of the Peripheral Interventions business for Boston Scientific. “We believe the Vessix Vascular Renal Denervation System will position us for leadership in this important market. We look forward to offering this technology to help patients better control their blood pressure, which also may lead to reduced healthcare costs associated with uncontrolled hypertension.”
Upon completion of the acquisition, Vessix Vascular will become part of the Peripheral Interventions business at Boston Scientific.
“Physician response to the V2 Renal Denervation System has been outstanding,” said Raymond W Cohen, chief executive officer at Vessix Vascular. “We are confident that the combination of the Vessix Vascular renal denervation technology with the Boston Scientific broad global clinical and commercial scale will result in a new standard for the treatment of uncontrolled hypertension.”
The agreement calls for an upfront payment of US$125 million, plus additional clinical- and sales-based milestones aggregating a maximum of US$300 million over the period between 2013 and 2017.
The V2 Renal Denervation System is an investigational device and not available for use or sale in the United States.
